BioSpace News Archive

PerkinElmer, Inc today announced the launch of its MaxSignal® Mycotoxin Automation Bundle .

AmerisourceBergen, a global healthcare company, bolstered its suite of manufacturer solutions through the addition of FirstView Financial.

BioAge Labs, Inc. today announced the appointment of Rekha Hemrajani and Jason Coloma to the company’s board of directors.

Agilent Technologies Inc. announces that researchers at the Indian Institute of Technology Bombay in India and the QIMR Berghofer Medical Research Institute in Australia have developed a rapid method for differentiating COVID-19-positive patients expected to show severe symptoms from those likely to experience only mild symptoms.

Helix BioPharma Corp. today announced that Dr. Krzysztof Saczek has been appointed as a member of the Board of Directors of the Company effective immediately.

Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) today announced dose administration for the first subject in the Phase 3b trial, EASE-SBS 4, evaluating glepaglutide, the company’s long-acting GLP-2 analog, which is being investigated as a potential treatment option for short bowel syndrome (SBS).

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today recruitment of Dr. Boris Reznik to the Company’s Advisory Board.

Guided Therapeutics, Inc. announced today it had passed the regulatory compliance review at the Department of Obstetrics & Gynecology Hospital of Fudan University located in Shanghai.

Vyant Bio, Inc. today announced a non-exclusive strategic collaboration combining Vyant Bio’s patient-derived complex organoid biology alongside Cyclica’s proteome-wide, Artificial Intelligence (“AI”) enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder (“CDD”), a severe neurodevelopmental epilepsy disorder with no effective treatments or cure.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, presented data from a preclinical study evaluating its lead investigational drug, Rhenium-186 Nanoliposome, in the treatment of leptomeningeal metastases, and presented plans for a Phase 1 clinical trial of 186RNL also in LM.